Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Outcomes Data For Pfizer's Inspra Could Give Heart Failure Drug A Jumpstart

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pfizer's heart failure drug Inspra (eplerenone) has been a spectacular commercial flop since it officially launched in 2004, but the drug could have renewed potential based on the results of new outcomes data. Pfizer announced May 27 that it is halting recruitment in an outcomes trial evaluating Inspra in a broader patient population early due to positive efficacy

You may also be interested in...



Bayer’s Finerenone Marches Forward, But Is Phase III Design Too Steep A Hill?

Heart failure drug's safety profile should become more clear – if the two-indication program hits the mark on dose selection and the evolving standard of care.

Pfizer Backs Out Of Cardiovascular R&D

Drug giant exits obesity, anemia, disease-modifying osteoarthritis and more.

Pfizer Launches Inspra; Will Help Company Reach $54 Bil. In 2004

Pfizer is beginning its launch of the congestive heart failure therapy Inspra

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel